

Cambridge University Press

978-0-521-52318-9 - Mechanisms of Disease: An Introduction to Clinical Science, Second Edition

Stephen Tomlinson, Anthony M. Heagerty, Anthony P. Weetman and Rayaz A. Malik

Index

[More information](#)

Index

Page numbers followed by '*f*' indicate figures; page numbers followed by '*t*' indicate tables.

- ACE inhibitors. *See* angiotensin converting enzyme (ACE) inhibitors
- acetaldehyde
adducts, toxicity, 251
metabolism, 246, 248
toxicity, 249
- N-acetyl cysteine, alcoholic liver disease, 258
- acid maltase deficiency, 46–7
- acidosis, malarial, 165
- ACS. *See* acute coronary syndrome (ACS)
- ACTH, 75–6
- activation domains, in gene transcription, 5
- activation induced cell death (AICD), 233
- activator protein-1 in PI signaling, 80
- acute coronary syndrome (ACS), 169, 175
acute myocardial infarction, 171, 174, 175, 176
angina, unstable, 170, 171, 173, 174
clinical scenario, 176
complications, 175
diagnosis, 174
risk factors, 171*t*
risk stratification, 174
symptoms/signs, 173
treatment, 174, 175
- acute myeloid leukemia, 56
- acute myocardial infarction, 171, 174, 175, 176
- acute phase proteins, cerebral ischemia, 204
- acute renal failure, malarial, 165
- acute respiratory distress syndrome (ARDS), 165, 165*f*
- acute rheumatic fever, 142*t*
- Addison's disease, 91
- adenylate cyclase, 77
- ADH (Alcohol dehydrogenase), 245, 248
- adhesion molecules, 87–9, 251
- adiponectin, 79
- adjuvants, in allergy, 121–2
- adrenaline, in trauma, 279
- adult respiratory distress syndrome (ARDS), 165, 165*f*
- advanced glycation end products (AGEs), 216
- agouti-related protein (AGRP), 76–7
- agrophobia, 292*t*
- AGRP (agouti-related protein), 76–7
- a-helix in protein synthesis, 8–9
- AICD (activation induced cell death), 233
- AIDS, 63–4, 142*t*. *See also* HIV-1 infection
- AIRE gene mutations, 91, 97
- alcohol
as enzyme inducer, 250
toxicity, 246, 248, 249
- alcohol abuse
clinical features, 296*t*
and psychiatric disorders, 293, 294, 300
- alcohol consumption
epidemiology, 243
safe limits, 243, 246
trauma and, 278
- alcohol dehydrogenase (ADH), 245, 248
- alcoholic hepatitis, 257
etiology, 246
T-cell immunity, 255
- alcoholic liver disease, 242, 258. *See also* alcoholic hepatitis; hepatic cirrhosis, acetaldehyde metabolism. *See* acetaldehyde
- adhesion molecules in, 251
- alcohol metabolism, 246
- CDT testing, 254
- clinical aspects, 252, 255, 259
- complement activation, 251

Cambridge University Press

978-0-521-52318-9 - Mechanisms of Disease: An Introduction to Clinical Science, Second Edition

Stephen Tomlinson, Anthony M. Heagerty, Anthony P. Weetman and Rayaz A. Malik

Index

[More information](#)

306 Index

- alcoholic liver disease (*cont.*)
 - complications, 253
 - cytokine markers, 255
 - diabetes mellitus, 247
 - enzyme induction in, 250
 - epidemiology, 243, 294
 - etiology, 243
 - fatty liver, 256
 - fibrosis, 246, 248, 252
 - hematology, 253
 - HLA antigens, 248
 - immunological abnormalities, 247, 254
 - isoenzyme relationship to, 248
 - liver testing, 254, 255
 - mechanisms of toxicity, 248
 - metabolism, genetic factors in, 247
 - reticuloendothelial system, 255
 - susceptibility, factors affecting, 247
 - T-cell immunity, 255
 - treatment, 258
 - white cell response, 251
- alcohol metabolism, 243–4
 - genetic factors in, 247
- aldose reductase inhibitors (ARIs), 216
- alglucerase, 58
- allergens, 121–2, 126–7
- allergic bronchopulmonary aspergillosis, 142*t*
- allergy, 115
 - adjuvants in, 121–2
 - anesthetics, 125
 - asthmatic reaction to. *See* asthma
 - atopy/exposure timing, 119–21
 - avoidance, 127
 - behavioral aspects, 116
 - cephalosporins, 125
 - clinical scenarios, 128–32
 - contrast media, 125
 - food. *See* food allergy
 - hyposensitization, 127
 - IgE mediated, 116–19, 120*f*
 - investigation, 126
 - latex, 124–5
 - local type I, 126
 - management, 127–8
 - mediator release, 119
 - mild reaction, 126
 - mimicry behaviors, 115–16
 - non-IgE mediated, 118, 123–4
 - parasites, response to, 120*f*
 - penicillin, 125
 - pulmonary effects, 119, 121*f*
 - reaction effect rescue, 128
 - response, evolution of, 122
 - target organs, 116–18
 - tissue secondary effects, 119, 121*f*
- Alstrom syndrome, 71
- aluminum hydroxide, 121–2
- amino acid requirements, in disease pathogenesis, 266
- amitriptyline, 219
- amphetamines, for obesity, 80
- amyotrophy, 211
- anaphylatoxins, 137
- anaphylaxis, 115, 122–3
 - fatal, 125
 - hydatid cyst rupture, 142*t*
 - nonallergic, 119–24
 - sensitization, 124–5
 - type I, 144
 - type II, 145
 - type III, 145
 - type IV, 145
- Anderson–Fabry disease, 43*t*, 48*t*
- androgen receptor mutations, 64–5
- anemia, 178
 - iron deficiency, 268
 - malarial, 163, 163*f*
 - pernicious, 102
- anergy, 88, 92–3
 - failure, in autoimmune disease initiation, 94–5
- anesthetics, allergy to, 125
- angina, unstable, 170, 171, 173, 174
- angioedema
 - clinical scenario, 132
 - hereditary, 116–19
 - mimicry of, 115–16
- angiotensin converting enzyme (ACE) inhibitors
 - allergic reactions to, 119–24
 - diabetic neuropathy, 217
 - in IgE mediated allergy treatment, 116–19
- angiotensin II, 184
- anorexia nervosa, 295
- ANP (atrial natriuretic peptide), 185
- Antabuse (disulphiram), 246
- anterior cerebral arteries, 193
- anterior communicating artery, 193
- antibiotics in allergic atopy, 119–21

- antibodies. *See also specific antibody*
in immune response, 85–6, 89–90, 98
- anticonvulsants, painful neuropathy, 219
- antigen-presenting cells (APCs)
in allergy, 121–2
in immune response, 86–7, 93, 231
TCR-CD3 complex binding, 140
thyroid autoantigen, response to, 106–8
- antisense gene therapy, 35–6
- anxiety disorder
characteristics of, 291, 292*t*
diagnosis, 288
- APCs. *See* antigen-presenting cells (APCs)
- apoptosis, in cell cycle regulation,
- appetite inhibition, 75–6
ACTH, 75–6
agouti-related protein, 76–7
CART neuropeptide, 76
corticotrophin-releasing hormone, 76
glucocorticoids, 75–6
 α MSH, 75–7
serotonin, 76
- appetite regulation
autonomic nervous system, 73
cholecystokinin, 73
CNS, 75
dopamine, 75
endogenous opioids, 75
enterostatin, 73
fatty acids, 73
galanin, 75
gastrin-releasing peptide, 73
GLP in, 73
glucose, 73
incretin, 73
lateral medial hypothalamus, 75
melanin concentrating hormone, 75
neuropeptide Y, 75, 76–7
norepinephrine, 75, 77
orexin A/B, 75
paraventricular nucleus, 75
physiologic, 73, 75*t*
substance P, 73
vagus nerve, 73
ventral medial hypothalamus, 75
- ARDS (acute respiratory distress syndrome), 165, 165*f*
- ARI's (aldose reductase inhibitors), 216
- arterial baroreceptor reflex, 277
- ascorbate assessment, 272*t*
- Ashkenazi Jews, Gaucher's disease in, 47, 49*f*, 50–2, 56–7
- Ashwell, Gilbert, 58
- Askanazy cells, 101–2
- aspartylglucosaminuria, 43*t*
- Aspergillus fumigatus*, 142*t*
- aspirin
sensitivity, 118
stroke/cerebral ischemia, 191, 205
unstable angina, 170, 171
- asthma
anaphylactic asphyxia, 123
daily control, 127
disease-modifying genes
treatment, 119, 121*f*
- atherothromboembolism, 197
- atopy in allergy, 119–21
- atrial natriuretic peptide (ANP), 185
- atrophic thyroiditis, 101, 104
- Austin's disease (multiple sulphatase deficiency), 42, 43*t*, 45
- autoagglutination, in malaria, 162
- autoimmune disease, 85–6. *See also specific disease*,
case studies, 111–13
effector mechanisms, 98
genetic factors affecting, 95–7
initiation, 94–5
nongenetic etiologies, 97–8
range, 101
treatment, 98–101
- autoimmune hypothyroidism, 101–2. *See also* Hashimoto's
thyroiditis (hypothyroidism),
etiology, 104
immunogenetics, 104–6
non-genetic factors, 106
thyroid autoantigen, response to, 106–8
- autoimmune polyglandular syndrome type 1, *AIRE* gene
mutations, 91
- autoimmune thyroid disease, 101
experimental, 102–4
- autoimmunity
HLA factors in, 85–6
immunogenetics and, 95–7
nongenetic etiologies, 97–8
prevention, 93
response, thyroid autoantigens, 106–8
- autonomic function testing, 213
- autonomic nervous system, 73
- avian erythroleukaemia membrane receptor, 18

- β 2-AR modifications, atopy/asthma
- B7, in TCR-CD3 complex binding, 140, 143*t*. *See also* CD80/CD86
- bacteria. *See also specific species*
- gram negative, 142*t*
- gram positive, 142*t*
- bacterial endocarditis, 145
- bacterial infections, 136. *See also specific infection*
- immune response to, 142*t*
- bacterial plasmids, 23
- bariatric surgery, 81–2
- basilar artery, 193
- BAT (brown adipose tissue), 77
- Batten's disease (neuronal ceroid lipofuscinosis, CLN), 43*t*
- BBB (blood-brain barrier), 200, 202
- B-cell lymphoma/leukaemia, Gaucher's disease, 56
- B-cells (humoral immunity)
- in delayed-type hypersensitivity response, 87–9
- as factor in autoimmune disease, 85–6
- in normal immune response, 89–90, 230
- T_H2 cells in, 144
- thyroid autoantigen, response to, 106–8
- tolerance, 93–4
- Bcl-2, in cerebral ischemia, 204
- BDNF (brain-derived neurotrophic factor), 217
- beta-2 agonists, 119
- beta-adrenergic system, in heart failure syndrome, 186
- bg-complex, in signal transduction, 10–11
- biliopancreatic diversion (BPD), 81–2
- blood-brain barrier (BBB), 200, 202
- blotting techniques, 26
- BMI (body mass index), 69, 71
- BNP (brain natriuretic peptide), 185
- body mass index (BMI), 69, 71
- body weight, physiologic regulation of, 73
- Borrelia recurrentis*
- immune response, 142*t*
- Jarisch-Herxheimer reaction, 140, 157
- BPD (biliopancreatic diversion), 81–2
- Brady, Roscoe, 58
- bradykinin, 116–19, 137
- brain-derived neurotrophic factor (BDNF), 217
- brain disease, 48, 50*t*
- brain natriuretic peptide (BNP), 185
- brown adipose tissue (BAT), 77
- b-sheet in protein synthesis, 8–9
- bulimia nervosa, 295
- N-butyldeoxygalactonojirimycin (NB-DGJ), 54*f*, 63–4
- N-butyldeoxynojirimycin, 54*f*, 63
- C1 esterase inhibitor
- allergic reactions to, 119–24
- in hereditary angioedema, 116–19
- C4, in immune response, 96–7
- c-*abl* proto-oncogene, 18
- calcineurin pathway, in heart failure syndrome, 187
- calcitonin, 6
- calcitonin gene-related peptide (CGRP), 6
- calcium fluctuation, in PI signaling, 13–15
- calcium transport proteins, 186, 188*f*
- calmodulin, 13–16
- cancer, 226. *See also specific disease*
- apoptosis abnormalities in, 21
- Candida* infections, 91
- capsaicin, 219
- carbamazepine, 219
- carbohydrate deficient form (CDT) testing, 254
- carbohydrate requirements, 267*t*
- cardiac autonomic neuropathy, 212
- cardiac troponin I (CTnI), 174
- cardiac troponin T (CTnT), 174
- cardioembolism, 197
- cardiovascular disease. *See also specific disease*
- depression and, 297, 299
- obesity and, 78, 79–80
- carotid artery circulation, 193
- CART neuropeptide, 76
- catalase, in alcohol metabolism, 246
- cathepsin proteins, 64–5
- CBF (cerebral blood flow), 196
- CCK (cholecystokinin), 73
- CCR5 in host cell entry, HIV-1, 150
- CD4+/CD8+ cells
- clonal deletion of, 90–1
- in EAT etiology, 102–4
- in HIV-1 infection, 149, 150, 152
- specific-acquired immunity, 143*t*
- TB/HIV-1, 154
- CD4/CD8 glycoproteins, 87–9, 233
- CD14
- in inflammation response, 138, 140
- modifications, atopy/asthma
- in tuberculosis, 148
- CD22, 143*t*
- CD28, in TCR-CD3 complex binding, 140, 143*t*
- CD36, cytoadherence mediation by, 162
- CD45R, 143*t*
- CD80/CD86, in T cell stimulation, 87–9, 233
- CDT (carbohydrate deficient form) testing, 254

Cambridge University Press

978-0-521-52318-9 - Mechanisms of Disease: An Introduction to Clinical Science, Second Edition

Stephen Tomlinson, Anthony M. Heagerty, Anthony P. Weetman and Rayaz A. Malik

Index

[More information](#)

- cefamandole, 246
- cell culture analysis, 36
 - clonal lines, 36–7
 - flow cytometry/FACS, 38
 - immortalisation, 37
 - immunoassay techniques, 38–40
 - immunocytochemistry, 38
 - primary culture, 36
 - protein detection, 37–8
- cell cycle regulation, 19–21
- central nervous system (CNS), in IgE mediated allergy, 116–19
- cephalosporin allergy, 125
- cerebral blood flow (CBF), 196
- cerebral circulation, 192, 192*f*
 - anterior (carotid) system, 193
 - posterior (vertebrobasilar) system, 193
- cerebral ischemia, 191, 192, 205
 - abbreviations, 209
 - acute phase proteins, 204
 - aspirin, 191, 205
 - blood-brain barrier, 200, 202
 - blood leukocyte recruitment/infiltration, 203
 - brain/body temperature, 203
 - cell death, 204
 - clinical presentation/classification, 193
 - clinical scenarios, 207
 - cortisol, 204
 - COX-2 (cyclooxygenase-2), 201, 202
 - cytokines, 200, 201, 202, 203
 - endothelin-1, 203
 - etiology, 196
 - evolution, 198
 - fibrinogen, 204
 - gene expression, 201, 201*f*
 - glial activation, 200
 - glucocorticoids, 204
 - HPA axis, 204
 - hypothalamic-pituitary-adrenal (HPA) axis, 204
 - ICAM-1, 201, 203
 - inflammatory response, 191, 200, 201
 - iNOS, 201, 202
 - interleukins in, 200, 201, 202
 - intravascular coagulation, 203
 - ischaemic cascade, 199*f*
 - MCA territory ischemia, 197
 - neuroprotection therapy, 191, 198, 205
 - nitric oxide synthase, 202
 - oxidative stress, 202, 204
 - reperfusion therapy, 198
 - tumor necrosis factor- α , 200, 201, 202
 - vascular tone changes, 203
- cerebrovascular disease
 - heart failure syndrome, 179
 - obesity, 78, 79–80
- Cerezyme (imiglucerase), 47–8, 58, 59–62
- Charcot neuroarthropathy, diabetic neuropathy, 220
- Chediak-Higashi syndrome, 43*t*
- chemical sequencing method, 27
- chemokine receptors in host cell entry, HIV-1, 150
- chemokines, 144*t*
 - Gaucher's disease, 64–5
 - in inflammation, 142
 - in innate immunity, 137
 - tuberculosis, 147
- chemoreceptor reflex, 278
- chimeric immune receptor, 235
- chitotriosidase, 55–6, 59–62, 63–4
- cholecystokinin (CCK), 73
- cholesterol(s)
 - acute coronary syndromes, 171*t*
 - in disease pathogenesis, 272
- cholesterol ester storage disease, 43*t*
- chondroitin sulphate A, cytoadherence mediation by, 162
- chromophilic tumors, 228
- chromophobic tumors, 228
- chromosome structure, 1–3
- chronic myeloid leukemia, 34
- ciliary neurotrophic factor (CNTF), 217
- circle of Willis, 193
- cis*-elements in gene transcription, 3
- CK-MB detection, 174
- classical receptor, 235
- clear cell carcinoma, 228
- CLN (neuronal ceroid lipofuscinosis), 43*t*
- clonal abortion/deletion, 85–6, 90–1
- clonal cell lines, 36–7
- clonidine, 219
- cloning
 - library screening, 24
 - library synthesis, 24
 - subtractive hybridisation, 24–5
 - vector. *See* vector cloning
- clotting system, innate immunity, 137
- CNS (central nervous system), in IgE mediated allergy, 116–19

Cambridge University Press

978-0-521-52318-9 - Mechanisms of Disease: An Introduction to Clinical Science, Second Edition

Stephen Tomlinson, Anthony M. Heagerty, Anthony P. Weetman and Rayaz A. Malik

Index

[More information](#)

310 Index

- CNTF (ciliary neurotrophic factor), diabetic neuropathy, 217
- cobalamin deficiency (*Cbl1F*), 43*t*
- Coley, William, 226
- collagens, heart failure syndrome, 188
- collecting duct carcinoma, 228
- collodion babies, 48, 50*t*, 53*f*, 54
- complementary DNA (cDNA), synthesis of, 22–3, 24
- complement system, 137, 279
- contrast media allergy, 124, 124*t*
- cooling threshold testing, 213
- co-receptor molecules in specific-acquired immunity, 140
- corneal opacities, in Gaucher's disease, 50*t*
- coronary heart disease. *See also specific disease*
heart failure syndrome, 179
obesity, 78, 79–80
- corticosteroids, 258
- corticotrophin-releasing hormone (CRH), 76
- corticotropin-releasing factor, 204
- cortisol, 204, 279
- co-stimulatory molecules
in anergy, 92–3
in specific-acquired immunity, 140
in T cell stimulation, 87–9, 143*t*
- COX-2 (cyclooxygenase-2), 201, 202
- C-peptide, diabetic neuropathy, 218
- C-reactive protein (CRP), 204
detection, 174
unstable angina, 170
- CREB, 16, 31
- CREM, 6
- cremophore, 124, 124*t*
- CREs (cyclic AMP response elements), 16
- CRH (corticotrophin-releasing hormone), 76
- CRP. *See* C-reactive protein (CRP)
- c-*src* proto-oncogene, 18
- CTLA-4, in TCR-CD3 complex binding, 140, 143*t*
- CTLA-4 polymorphisms
in autoimmune hypothyroidism, 104–6
in Grave's disease, 108
in immune response, 97
- CTLs (cytotoxic T cells), 230
- CTnI (cardiac troponin I), 174
- CTnT (cardiac troponin T), 174
- Cushing's syndrome/depression, 292
- CXCR4, in HIV-1 host cell entry, 150
- cyclic adenosine diphosphate-ribose (cyclic ADPR), 13–15
- cyclic adenosine monophosphate (cAMP)
formation, G proteins in, 77
in signal transduction, 16
TSH receptor antibodies, 108–10
- cyclic AMP response elements (CREs), 16
- cyclooxygenase-2 (COX-2), 201, 202
- cyclosporin A, 98–01
- cysteine, in gene transcription, 3–4
- cystic fibrosis, deletion mutations in, 33
- cystinosis, 42, 43*t*, 45, 48*t*
- cytoadherence, in severe malaria, 162
- cytochrome P450, 250
- cytokines, 144*t*
in allergic atopy, 119–21
in anergy, 92–3
cerebral ischemia, 200, 201, 202, 203
heart failure syndrome, 184
in IgE mediated allergy, 116–19
in inflammation, 142, 142*f*. (*See also* proinflammatory cytokines)
in malaria, 162, 163
markers, alcoholic liver disease, 255
in ophthalmopathy, 110, 111–12
proviral transcription, HIV-1, 150
release, renal cell carcinoma, 227
in T cell stimulation, 87–9
T_H1/T_H2 cells, 144
thyroid autoantigen, response to, 106–8
- cytotoxic T cells (CTLs), 230
- D409H mutations, in Gaucher's disease, 52–4
- DAG (1, 2-diacylglycerol), 217
- Dale, Henry, 118
- Danon's disease, 43*t*
- DCM (dilated cardiomyopathy), 179
- de Duve, Christian, 42, 45, 58
- delayed-type hypersensitivity, 87–9, 145, 147
- deletions, Southern blotting analysis, 32
- deliberate self-harm, 294, 295*t*
- delirium
clinical scenario, 292, 301
etiology, 295*t*
mental state abnormalities, 293*t*
- dendritic cells, in allergic atopy, 119–21
- depression
as cardiac mortality risk factor, 297
clinical scenarios, 289, 298, 299
diagnosis, 288
epidemiology, 288, 290

Cambridge University Press

978-0-521-52318-9 - Mechanisms of Disease: An Introduction to Clinical Science, Second Edition

Stephen Tomlinson, Anthony M. Heagerty, Anthony P. Weetman and Rayaz A. Malik

Index

[More information](#)

- health behavior and, 293
- organic disease and, 292
- treatment, 289, 290, 291
- depressor reflex, 277
- determinant spreading, autoimmune hypothyroidism, 106–8
- dextran, 124, 124*t*
- diabetes mellitus
 - acute coronary syndromes, 172
 - alcoholic liver disease, 247
 - BMI and, 69, 263*f*
 - conceptualization of, 262
 - genetic factors, 95
 - heart failure syndrome, 179, 189
 - macronutrient balance in, 264
 - obesity and, 69, 78–9
 - psychiatric disease and, 301
 - Three Pillars of Human Nutrition, 264*t*
 - thymectomy induction of, 102
 - treatment, 98–101
- diabetic neuropathy, 221
 - autonomic function testing, 213
 - axonal degeneration, 214
 - cardiac autonomic, 212
 - Charcot neuroarthropathy, 220
 - classification, 210
 - clinical scenarios, 224
 - C-peptide, 218
 - cranial mononeuropathies, 211
 - demyelination, 214
 - distal sensory, 211
 - electrophysiology testing, 214
 - epidemiology, 210
 - erectile dysfunction, 212, 220
 - focal/multifocal, 210
 - foot ulceration, 220, 221*f*
 - gastrointestinal, 212
 - gastroparesis, 212, 213, 220
 - glycation, 216
 - growth factors, 217
 - hedgehog proteins, 218
 - hyperglycemia, 216
 - immune mechanisms, 218
 - insulin-like growth factor, 217
 - mononeuropathies, 211
 - muscle infarction, 222*f*
 - oxidative stress, 216
 - painful, 212, 216, 219
 - pathology testing, 214
 - proximal motor, 211
 - quantitative sensory tests, 213
 - risk factors, 215
 - sweating abnormalities, 213, 220
 - symptom quantification, 213
 - truncal, 211
 - vascular factors, 217
 - VEGF, 218
- diabetic ophthalmoplegia, 211
- diacylglycerol (DAG), 13
- diarrhea and malabsorption, 265
- DIC (disseminated intravascular coagulation), 165
- dideoxy sequencing method, 26–7
- diet
 - effect on health status, 265
 - very low calorie (VLCD), 80
- dietary exposure, 265
- dietary therapy, for obesity, 80
- dilated cardiomyopathy (DCM), 179
- dimerization, leucine zippers in, 4
- disease mechanisms, historical views of, 262
- disseminated intravascular coagulation (DIC), 165
- distal sensory neuropathy, 211
- disulphide bridges in protein synthesis, 8–9
- disulphiram (Antabuse), acetaldehyde metabolism, 246
- DNA
 - abnormal, analysis of, 32–5
 - complementary, synthesis of, 22–3, 24
 - intergenic, function of, 2
 - structure of, 1–2
- dominant negative receptor mutants, targeted, 32
- dopamine, 75
- DRB1*0302* allele in autoimmune hypothyroidism, 104–6
- drug abuse in psychiatric disorder development, 294
- dyslipidaemia, 78
- eating disorders, 295, 297*t*
- EBV (Epstein-Barr virus), 56–7, 142*t*
- Echinococcus granulosus*, 142*t*
- effector elements, 9
- EGF (epidermal growth factor), 9–10
- Ehrlich, Paul, 85–6
- elderly patients, delirium in, 292
- embryonic stem cells, 30–1
- emotional response to disease, normal, 286
- endogenous opioids, 75
- endonucleases (restriction)
 - methods of investigation, 22
 - in subtractive hybridisation, 24–5

Cambridge University Press

978-0-521-52318-9 - Mechanisms of Disease: An Introduction to Clinical Science, Second Edition

Stephen Tomlinson, Anthony M. Heagerty, Anthony P. Weetman and Rayaz A. Malik

Index

[More information](#)

312 Index

- endothelin-1 (ET-1), 203
- energy expenditure
 - brown adipose tissue, 77
 - exercise, 77
 - free fatty acids, 77
 - leptin stimulation of, 76–7
 - regulation, 77
 - uncoupling proteins, 77
- energy requirements, in disease, 264, 267*t*
- enhancer elements in gene transcription, 3
- enterostatin, 73
- entrapment neuropathies, 211
- environmental factors, in obesity, 72–3
- enzyme(s). *See also specific enzyme*
 - lysosomal, 42–5, 46–7, 55–6
 - methods of investigation, 21–2
- enzyme replacement therapy, for lysosomal storage
 - diseases, 46–8, 57–62
- epidermal growth factor (EGF) in signal transduction, 9–10
- epitopes, 86–9
- Epstein–Barr virus (EBV), 56–7, 142*t*
- erectile dysfunction, in diabetes, 212, 220
- erythema nodosum leprosum, 142*t*
- estrogen(s), 97–8, 106
- estrogen receptors, 10
- ET-1 (Endothelin-1), 203
- ethanol. *See* alcohol
- ethnicity, body mass index and, 69, 72–3
- excitotoxicity, 200, 205
- exercise
 - and energy expenditure in obesity, 77
 - in obesity treatment, 79–80
- experimental autoimmune thyroiditis (EAT), 102–4
- expression vectors in library screening, 24

- Fabry's disease, 60–2, 62*t*
- FACS (fluorescence activated cell sorting), 38
- Farber's disease, 43*t*
- Fas antigen, 97
- fat mass (FM), 70
- fat requirements, 267*t*
- fat topography in obesity, 69–70
- fatty acids, 73
- Fc ϵ RI β modifications, atopy/asthma
- Fenfluramine, for obesity, 80
- fever, malarial, 161
- FFA (free fatty acids), 77
- FFM (free fat mass), 70
- fibrinogen, 170, 204
- fibrinolytic system, innate immunity, 137
- fibrolytic agents, 170, 171
- fibrosis
 - in alcoholic liver disease, 246, 248, 252
 - cystic, deletion mutations in, 33
 - in heart failure syndrome, 188
 - hepatic. *See* hepatic fibrosis
- floxuridine, 229
- fluorescence activated cell sorting (FACS), 38
- 5-fluorouracil (5-FU), 229
- FM (fat mass), 70
- folate, 271
 - assessment, 272*t*
- food allergy
 - adjuvants in, 121–2
 - avoidance, 127
 - classification, 117*f*
 - clinical scenarios, 128, 131
 - differential diagnosis, 115–6
 - fatal, 125
 - sensitization, 124–5
 - symptoms, 126
- foot ulceration, diabetic, 220
- FOXP3* gene mutations, 97
- frameshift mutations, in Gaucher's disease, 52
- free fat mass (FFM), 70
- free fatty acids (FFA), 77
- fucosidosis, 43*t*, 46–7
- fungi, immune response to, 142*t*
- fusion receptor, 235

- gabapentin, 219
- galactosialidosis, 43*t*
- galanin, 75
- gamma glutamyl transferase (gamma GT), 254
- gammopathies, in Gaucher's disease, 56
- gangliosidosis, 43*t*, 48*t*
- gastric banding, 81
- gastrin-releasing peptide, 73
- gastrointestinal neuropathy, 212
- gastroparesis, diabetic, 212, 213, 220
- Gaucher, Phillipe, 48
- Gaucher's disease, 42, 43*t*, 47, 49*f*, 65
 - alternative treatment, 62
 - beta cell proliferative responses, 56, 60–2
 - biochemical genetics, 50, 52–4
 - clinical manifestations, 52–4
 - clinical subtypes, 50*t*
 - clinical trials, 63–4

- course, 56–7
- diagnosis, 52
- enzyme replacement therapy, 46–8, 57–62, 62*t*
- epidemiology, 48*t*
- family screening, 52
- iminosugars, 54*f*, 63
- lysosomal enzymes, 55–6
- lysosome complementation, 46–7
- metabolic abnormalities, 55
- neuronopathic, 48–50, 52–4, 56–7, 59
- Parkinson's disease and, 55
- pathology, 50, 50*t*
- pathophysiology, 64–5
- rare manifestations of, 54
- substrate reduction, 62–3
- treatment, 57–62
- GCS (Glasgow Coma Scale), 281
- gelatines, modified, allergic reactions to, 124, 124*t*
- gel electrophoresis, 25–6
- gender differences, in autoimmune hypothyroidism, 106
- gene expression, in cerebrovascular disorders, 201, 201*f*
- generalized anxiety disorder, 292*t*
- gene structure, 1–3
- gene targeting, by homologous recombination, 31–2
- gene therapy, 35
 - antisense, 35–6
 - for homozygous familial hypercholesterolaemia, 35
- genetic factors
 - in alcohol metabolism, 247
 - in autoimmune disease, 95–7, 104–6
 - in diabetes mellitus, 95
 - in hyperthyroidism, 95
 - in obesity, 71–2
- genetic mutations. *See also specific disease or mutation*
 - dominant negative receptor, targeted, 32
 - in Gaucher's disease, 50, 51*f*, 52, 56–7
 - G protein alterations, 18
 - kinase, 18
 - lysosomal acid hydrolases, 42–5
 - in malaria, 166
 - membrane receptor alterations, 18
 - methods of analysis, 33–5
 - in obesity, 71, 75–7
 - p53, 19–20
 - production of, transgenics, 31–2
 - Rb gene, 20–1
 - transcription factors, 19
- gene transcription, 3
 - factors, 3–5, 65
 - methods of analysis, 28–9
 - regulation, tissue specificity in, 5
 - signaling pathway effects, 16–7
- genome, human, 1–3
- glandular fever, 157
- Glasgow Coma Scale (GCS), 281
- glial activation, cerebral ischemia, 200
- glomerulonephritis, 142*t*
- GLP, in appetite regulation, 73
- glucagon response in trauma, 279
- glucocerebrosidase, 46–7
- glucocerebroside, 62–3
- glucocorticoid(s)
 - in appetite inhibition, 75–6
 - for autoimmune diseases, 98–101
 - in autoimmunity, 97–8
 - for cerebral ischemia, 204
 - for tuberculosis, 148
- glucocorticoid receptors, 10, 19
- glucose, 73
 - metabolism, in alcoholic liver disease, 249
- α -glucosidase, 60, 62*t*
- glucosylceramidase (β -glucosidase, glucocerebrosidase),
 - 48, 50, 51*f*, 52, 57–63
- glucosylceramide, 55
- β -glucuronidase deficiency, 46–7
- glycation, in diabetic neuropathy, 216
- glycine, 266
- glycogen storage diseases (GSDs), 43*t*
- p-glycoprotein, renal cell carcinoma, 229
- glycoproteinoses, 43*t*
- glycosylation, in protein synthesis, 8–9
- glycosylphosphatidylinositol (GPI), 161
- GM₂ activator, 43*t*
- gold, 98–101
- G protein(s), 10–11, 18
- G-protein-independent receptors, 9–10, 18
- G-protein-linked receptors, 9, 18
- gram negative bacteria, 142*t*
- gram positive bacteria, 142*t*
- granulomas, tuberculosis, 146*f*
 - HIV coinfection and, 154
- Graves' disease (hyperthyroidism), 101, 108
 - case study, 112–3
 - etiology, 85–6, 108
 - genetic factors, 95
 - membrane receptor alterations in, 18
 - ophthalmopathy, 110, 111–2
 - TSH receptor antibodies, 108–10

- growth factors, in diabetic neuropathy, 217
 GRP (gastrin-releasing peptide), 73
 GSDs (glycogen storage diseases), 43*t*
- HAART (highly active antiretroviral treatment), 155, 158
 haematopoiesis, extramedullary, 50, 50*t*
Haemophilus influenzae b, 140, 142*t*
 Hageman Factor, 137
 Hashimoto's thyroiditis (hypothyroidism), 101–2
 depression in, 292
 etiology, 85–6, 104
 iodine intake and, 106
 ophthalmopathy, 110, 111–12
 HDLs (high-density lipoproteins), 172
 health, diet and, 265
 heart disease. *See* cardiovascular disease; *specific disease*
 heart failure syndrome, 178, 179*f*
 cardiac hypertrophy and, 183*f*
 clinical scenarios, 189
 etiology, 179, 179*t*
 fibrosis, 188
 Frank-Starling mechanism, 182, 182*f*
 gene expression alteration, 185, 187
 kidney hyperperfusion and, 183, 183*f*
 neurohumoral activation/endothelial dysfunction and, 183*f*
 NYHA classification, 181*t*
 protein expression, 185, 186
 symptoms, 179*t*
 systolic *versus* diastolic, 182
 heat shock protein 90 (hsp-90), 10
 hedgehog proteins, in diabetic neuropathy, 218
 helix-turn-helix motifs, in gene transcription, 71
 helper (T_H) cells (CD4+ cells), 87–9, 90–1
 hemodynamic infarction, 197
 hemoglobin mutations, in malaria, 166
 hepatic cirrhosis, 257
 etiology, 246
 T-cell immunity, 255
 hepatic disease. *See also specific disease*
 non-metastatic, 227
 hepatic fibrosis
 Gaucher's disease, 50*t*, 56–7, 65
 Schistosoma mansoni, 142*t*
 hepatic hypoxia, 249
 hepatitis B virus, 253
 hepatosplenomegaly, 50, 50*t*
 Hermansky-Pudlak syndrome, 43*t*
 Hers, Henri-Géry, 42, 46–7
 heterogeneous nuclear (hnRNA), 5–6
 high-density lipoproteins (HDLs), 172
 highly active antiretroviral treatment (HAART), 155, 158
 histamine, 116–19, 128
 histidine, 3–4
 HIV-1 infection
 CD4+/CD8+ cells in, 149, 150, 152
 Gaucher's disease, 63–4
 immune activation/pathogenesis, 152, 153*f*
 immunopathology, 142*t*
 life cycle, 149*f*
 macrophages, 151
 replication, antigen presentation, 151, 152*f*
 reverse transcription in, 150, 151*f*
 tuberculosis, 147, 155*f*
 HLA (human leukocyte antigen)
 alcoholic liver disease, 248
 in autoimmune hypothyroidism, 104–6
 as factor in autoimmune disease, 85–6
 formation, in immune response, 86–7, 143*t*
 linkage disequilibrium in, 96–7
 mutations, malaria, 166
 HLA-DR3
 in autoimmune hypothyroidism, 104–6, 143*t*
 in Grave's disease, 108
 Hodgkin's disease, 56
 homologous recombination, 31–2
 homozygous familial hypercholesterolaemia, 35
 hormones, 97–8, 108. *See also specific hormone*
horror autotoxicus, 85–6
 host cell entry, HIV-1, 150
 HPA (hypothalamic-pituitary-adrenal) axis, 204
 hsp-90 (heat shock protein 90), 10
 human genome, 1–3
 human immunodeficiency virus-1. *See* HIV-1 infection
 human leukocyte antigen. *See* HLA (human leukocyte antigen)
 Hunter's disease, 60–2, 62*t*
 Huntington's disease, 2–3
 Hurler's disease, 60, 62*t*
 Hurler-Scheie disease, 60–2, 62*t*
 Hurthle cells, 101
 hyaluronic acid, 162
 hydrogen bonding, DNA, 1–2
 hydroxymethylglutaryl CoA reductase inhibitors, 217
 hygiene hypothesis, 119–21
 hypercalcemia, 227
 hypercholesterolemia, 189
 hypergammaglobulinaemia, 56

- hyperglycaemic neuropathy, 212
- hyperglycemia, 216
- hyperinsulinaemia, 77, 78–9
- hyperlacticaemia, 249
- hyperlipidemia, 172
- hypersensitivity. *See* allergy; anaphylaxis
- hypersplenism, 48, 49*f*
- hypertension
 - acute coronary syndromes, 171*t*
 - heart failure syndrome, 179, 184, 188*f*
 - in obesity, 77, 271
 - renal cell carcinoma, 227
- hyperthyroidism. *See* Graves' disease (hyperthyroidism)
 - 85, 101
- hypoglycemia, 115–16, 165
- hypomania development, health behaviors in, 295
- hypoparathyroidism, *AIRE* gene mutations, 91
- hypothalamic-pituitary-adrenal (HPA) axis, cerebral ischemia, 204
- hypothalamus, 74*f*, 75–6
- hypothyroidism. *See* Hashimoto's thyroiditis (hypothyroidism)
- ICAM-1. *See* intercellular adhesion molecule-1 (ICAM-1)
- I-cell disease, 43*t*, 46–7
- ichthyosis, 50*t*
- idiopathic environmental intolerance, 115–16
- Id protein, 5
- IGF (insulin-like growth factor), 46–7, 217
- IGT. *See* impaired glucose tolerance (IGT)
- imiglucerase (Cerezyme), 47–8, 58, 60, 62*t*
- iminosugar treatment, 54*f*, 63
- imipramine, 219
- immune response. *See also specific disease*
 - AIRE* gene mutations in, 97
 - antibody production in, 85–6, 89–90, 98
 - antigen presentation, 86–7, 93, 231
 - to bacterial infections, 142*t*
 - B-cells in, 89–90, 230
 - C4 in, 96–7
 - chimeric immune receptor, 235
 - CTLA-4 polymorphisms in, 97
 - in disease pathogenesis, 137*f*. *See also* immunopathology
 - Fas antigen in, 97
 - FOXP3* gene mutations in, 97
 - HLA factors in, 85–7, 143*t*
 - IgE mediated allergy, 119
 - immunoglobulins in, 85–6
 - innate. *See* innate immune response
 - lysosomes in, 86–7
 - macrophages in, 141*f*
 - MHC class I, 231, 233
 - MHC class II, 86–9, 90–1, 231, 233
 - NOD2* gene, 97
 - normal, 86, 230
 - parasites, 142*t*
 - self/nonself discrimination, 90–4
 - T cell stimulation, 87–9, 143*t*
 - tumor necrosis factor- α , 96–7
 - to viral infections, 56–7, 142*t*
- immunoassay techniques, 38–40
- immunocytochemistry, 38
- immunogenetics, 95–7, 104–6
- immunoglobulin A (IgA), 254
- immunoglobulin E (IgE), 116–19, 121–2, 126
- immunoglobulin G (IgG), 106–8, 254
- immunoglobulin M (IgM), 106–8
- immunoglobulins, 85–6, 89
- immunometric assays, 40
- immunomodulating drugs, 148
- immunopathology, 136
 - HIV-1 infection, 142*t*
 - innate immunity, 140, 142*t*
 - specific-acquired immunity, 142*t*
 - tuberculosis, 147*f*
- impaired glucose tolerance (IGT)
 - acute coronary syndromes, 172
 - hyperglycemia, 216
 - predisposing factors, 262
- incretin, 73
- inducible nitric oxide synthase (iNOS), 201, 202
- infantile atopic eczema, 125
- infants, Gaucher's disease in, 50*t*, 52–4
- infections. *See also* bacterial infections; parasitic infections; viral infections; *specific infection*
 - in allergic atopy, 119–21
 - in autoimmune hypothyroidism, 106
 - in autoimmunity, 97–8
 - in Grave's disease, 108
- infectious mononucleosis, 142*t*
- inflammation
 - acute, triggers, 138
 - CD14 in, 138, 140
 - cerebral ischemia, 191, 200, 201
 - chemokines in, 142
 - chronic, 144

Cambridge University Press

978-0-521-52318-9 - Mechanisms of Disease: An Introduction to Clinical Science, Second Edition

Stephen Tomlinson, Anthony M. Heagerty, Anthony P. Weetman and Rayaz A. Malik

Index

[More information](#)

316 Index

- inflammation (*cont.*)
- cytokines in, 142, 142*f*. *See also* proinflammatory cytokines
 - interleukins in, 142, 142
 - mediators, 137
 - metabolism in, 264
 - tumor necrosis factor- α , 142, 144
 - unstable angina, 170
- innate immune response, 136
- acute, triggers, 138
 - immunopathology, 140, 142*t*
 - inflammatory mediators, 137
 - mediators, 137
 - process, 138
 - sepsis, bacterial, 140, 142*t*
- iNOS (inducible nitric oxide synthase), cerebral ischemia, 201, 202
- inositol 1, 4, 5-triphosphate (IP₃), 13, 14*f*, 16
- insect venom
- as allergen, 121
 - avoidance, 127
 - clinical scenario, 128–9, 131–2
 - fatal, 125
- insulin-like growth factor (IGF), 46–7, 217
- insulin neuritis, 212
- insulin response
- in obesity, 77, 78–9
 - in trauma, 279
- intercellular adhesion molecule-1 (ICAM-1)
- alcoholic liver disease, 251
 - cerebral ischemia, 201, 203
 - cytoadherence mediation by, 162
 - mutations, malaria, 166
 - TCR-CD3 complex binding, 140, 143*t*
 - thyroid autoantigen, response to, 106–8
- interferon(s), in renal cell carcinoma, 229, 234
- interferon- α (IFN- α), 144*t*
- interferon γ (IFN- γ), 144*t*
- in anergy, 92–3
 - chronic inflammation, 144
 - in T cell stimulation, 233
 - thyroid autoantigen, response to, 106–8
 - tuberculosis, 147
 - unstable angina, 170
- intergenic DNA, function of, 2
- interleukin(s), 79, 142
- interleukin-1 (IL-1), 144*t*
- alcoholic liver disease, 255
 - cerebral ischemia, 200, 201, 202
 - heart failure syndrome, 184
 - in inflammation, 142
 - in malaria, 163
 - proviral transcription, HIV-1, 150
 - in trauma, 279
 - tuberculosis, 148
- interleukin-2 (IL-2), 144*t*
- in autoimmune disease initiation, 94–5
 - proviral transcription, HIV-1, 150
 - renal cell carcinoma, 234, 235
 - T cell stimulation by, 87–9, 93, 233
- interleukin-4 (IL-4), 144*t*
- in allergic atopy, 119–24
 - modifications, atopy/asthma
- interleukin-5 (IL-5), 144*t*
- interleukin-6 (IL-6), 144*t*
- alcoholic liver disease, 255
 - cerebral ischemia, 201, 202
 - heart failure syndrome, 184
 - in inflammation, 142
 - Jarisch-Herxheimer reaction, 140
 - in malaria, 163
 - in obesity, 79
 - proviral transcription, HIV-1, 150
 - in trauma, 279
 - tuberculosis, 148
 - unstable angina, 170
- interleukin-7 (IL-7), 144*t*
- interleukin-8 (IL-8), 144*t*
- alcoholic liver disease, 255
 - Jarisch-Herxheimer reaction, 140
 - in malaria, 163
 - in trauma, 279
 - tuberculosis, 147
- interleukin-10 (IL-10), 144*t*
- interleukin-12 (IL-12), 144*t*
- interleukin-13 (IL-13), 119–24
- interleukin-18 (IL-18), 255
- internal carotid artery, 193
- intrathymic tolerance, 92–3
- iodine intake, 106, 108
- IP₃ (inositol 1, 4, 5-triphosphate), 13, 14*f*, 16
- IPEX syndrome, 97
- iron deficiency anemia, 268
- ischemic cascade, 199*f*
- ischemic core, 198
- ischemic penumbra, 198, 204

- Janus kinases, 9–10
- Jarisch-Herxheimer reaction, 140, 157
- jellyfish venom, 121
- Jun protein, structure/activation, 17
- keratopalmar periodontitis (Papillon-Lefèvre syndrome), 43*t*
- kidney cancer. *See* renal cell carcinoma (RCC)
- kinase mutations, 18
- kinin system, 137
- Krabbe's disease, 43*t*, 48*t*
- lacunar infarctions (LACI), 196, 196*f*
- LAM (lipoarabinomannan), 147
- laparoscopic gastric banding (Lap-Band), 81
- Laron-type dwarfism, membrane receptor alterations in, 18
- laryngeal edema, mimicry of, 115–16
- lateral medial hypothalamus, 75
- latex allergy, 124, 125
- Laurence Moon-Biedl syndrome, 71
- LDLs (low-density lipoproteins), 172
- lens protein, 94–5
- leprosy, 142*t*
- leptin mutation, 71, 76–7
- leptin receptor mutation, 71, 76–7
- Leptospira* spp., 140
- leucine zippers, in gene transcription, 4
- leukotriene B₄ (LTB₄), 137
- leukotrienes, in IgE mediated allergy, 116–19
- LFA1/2, 143*t*
- LH (luteinising hormone), 18
- lidocaine, 219
- ligases, 22
- linkage disequilibrium, 96–7, 104–6
- lipid disorders, 43*t*, 172
- lipid inflammatory mediators, 137
- lipid metabolism, in alcoholic liver disease, 249
- lipoarabinomannan (LAM), 147
- lipogenesis, 249
- liver disease. *See specific disease*
- low-density lipoproteins (LDLs), 172
- lung cancer, small cell, 20–1
- lung disease. *See specific disease*
- luteinising hormone (LH), 18
- lymphadenectomy, 228
- lymphocytes
- in allergic atopy, 119–24
 - in autoimmunity, 94–5, 97–8, 143*t*
- lysosomal acid hydrolases, 42–5, 55
- lysosomal recognition markers, 46–7
- lysosomal storage diseases, 42, 43*t*, 45. *See also specific disease*
- enzyme replacement therapy, 46–8, 57, 62*t*
 - epidemiology, 48*t*
- lysosomes, 42, 45–6
- complementation mechanism, 46–7
 - in immune response, 86–7
 - targeting mechanism defects, 46–7
- macronutrient requirements, in disease, 264, 267*t*
- macrophages
- ACS plaques, 170
 - Gaucher's disease, 48, 49*f*, 57, 62*t*, 63–4, 65
 - HIV-1 infection, 151
 - in immune response, 141*f*
 - in receptor-mediated endocytosis, 42
- major histocompatibility complex (MHC). *See also* HLA (human leukocyte antigen)
- in antigen presentation, 231
 - TCR-CD3 complex binding, 140, 230
- α -major histocompatibility complex (MHC), 185
- β -major histocompatibility complex (MHC), 185
- major histocompatibility complex (MHC) class I
- in autoimmune disease, 95–6
 - in immune response, 231, 233
 - thyroglobulin, autoimmune response to, 102–4
- major histocompatibility complex (MHC) class II
- in anergy, 92–3
 - in autoimmune disease, 95–6
 - in immune response, 86–9, 90–1, 231, 233
 - thyroglobulin, autoimmune response to, 102–4
 - thyroid autoantigen, response to, 106–8
- malabsorption, consequences of, 265
- malabsorptive/restrictive surgery, 81–2
- malaria, 160, 167
- acidosis, 165
 - acute renal failure, 165
 - anemia, 163, 163*f*
 - cerebral, 161*f*
 - clinical scenarios, 168
 - coma/convulsions, 164, 164*f*
 - disseminated intravascular coagulation, 165
 - febrile illness, 161, 161*f*
 - hypoglycaemia, 165
 - mutations, 166
 - pathogenesis, 163
 - plasmodial life cycle/disease manifestation, 160

Cambridge University Press

978-0-521-52318-9 - Mechanisms of Disease: An Introduction to Clinical Science, Second Edition

Stephen Tomlinson, Anthony M. Heagerty, Anthony P. Weetman and Rayaz A. Malik

Index

[More information](#)

318 Index

- malaria (*cont.*)
 pulmonary edema/ARDS, 165, 165*f*
 severe, 161
 severity determination, 167
 manganese toxicity, 269
 mannose 6-phosphate
 binding, 46–7
 in therapeutic protein delivery, 47, 60, 62*t*
 α -mannosidosis, 43*t*, 48*t*
 β -mannosidosis, 43*t*
 MAO inhibitors, 293
 Maroteaux-Lamy disease, 43*t*, 62*t*
 mast cells, 119, 122
 mast cell tryptase, 126
 mastocytosis, 126
 matrix metalloproteinases, 170, 216
 MC4-R mutation, in obesity, 71, 75–6
 MCA territory ischemia, 197, 198*f*
 McGill pain questionnaire, 213
 MCH (melanin concentrating hormone), 75
 megestrol (Megace), 229
 melanin concentrating hormone (MCH), 75
 membrane receptors
 alterations, 18
 in signal transduction, 9–10, 18
 MEOS (mitochondrial ethanol oxidising system), 245
 meralgia paraesthetica, 211
 messenger RNA (mRNA)
 methods of analysis, 28–9
 in protein synthesis, 75–6
 translation of, 6–7
 metabolic syndrome, 262, 272, 273
 metabolism, in disease states, 264
 metachromatic leukodystrophy, 43*t*, 46–7, 48*t*
 metronidazole, 246
 mexiletine, 219
 MHC. *See* major histocompatibility complex (MHC)
 microvasculature, in IgE mediated allergy, 116–19
 middle carotid artery, 193
 miglustat (Zavesca), 54*f*, 63–4
 MIP-1 α / β , 144*t*
 missense mutations, in Gaucher's disease, 52, 53*f*
 mitochondrial ethanol oxidising system (MEOS), 245
 MOFS (multiple organ failure syndrome), 282
 molecular biology, methods of investigation, 21
 cDNA synthesis, 22–3, 24
 enzymes, 21–2
 molecular mimicry, 98
 monoamine theory of depression, 289
 monoclonal antibodies
 fever, malarial, 161
 in protein detection, 37–8
 as treatment for autoimmune diseases, 98–101
 mononeuritis multiplex, 211
 Morquio diseases, 43*t*
 MPS. *See* mucopolysaccharidoses (MPS)
 α MSH, 75–7
 mucopolipidosis, 43*t*
 mucopolysaccharidoses (MPS), 43*t*, 45–7
 enzyme replacement therapy, 62*t*
 epidemiology, 48*t*
 multiple myeloma, 56
 multiple organ failure syndrome (MOFS), 282
 multiple sulphatase deficiency (Austin's disease), 42, 43*t*, 45
Mycobacterium avium infection, 150
Mycobacterium leprae, 142*t*
Mycobacterium tuberculosis. *See also* tuberculosis, 144, 145
 myocardial infarction, acute, 171, 174, 175, 176
 MyoD factor, 5
 myotonic dystrophy, 33–4
 myxoedema, primary, 85–6

 Na/Ca exchanger, in heart failure syndrome, 186
 NASH (non-alcoholic hepatic steatosis), 271
 NB-DGJ (N-butyldeoxygalactonojirimycin) treatment, 54*f*, 63–4
 necrosis, osseous, 48, 50*t*, 56, 65
 NEFA (non-esterified fatty acid), 69–70, 78–9
 nephrectomy, 228
 nerve conduction velocity, 216
 nerve growth factor (NGF), 217
 Neufeld, Elisabeth, 46
 neurodegeneration, apoptosis abnormalities in, 21
 neuronal ceroid lipofuscinosis (CLN), 43*t*
 neuropathy, diabetic. *See* diabetic neuropathy
 neuropathy symptom score (NSS), 213
 neuropeptide Y (NPY), 75, 76–7
 neuroprotection therapy, 191, 198, 205
 neurotrophin(s), 217
 neurotrophin-3 (NT-3), 217
 Nexavar (sorafenib), 238
 NFAT transcription factors, in heart failure syndrome, 187, 188*f*
 NF- κ B pathway
 proviral transcription, HIV-1, 150, 151*f*
 stroke/cerebral ischemia, 201
 NGF (nerve growth factor), 217

Cambridge University Press

978-0-521-52318-9 - Mechanisms of Disease: An Introduction to Clinical Science, Second Edition

Stephen Tomlinson, Anthony M. Heagerty, Anthony P. Weetman and Rayaz A. Malik

Index

[More information](#)

- niacin assessment, 272*t*
- Niemann-Pick diseases, 43*t*
 - enzyme replacement therapy, 62*t*
 - epidemiology, 48*t*
 - treatment, 60, 62*t*
- nitric oxide, 172, 184
- nitric oxide synthase (NOS), 202
- NOD2* gene, 97
- non-alcoholic hepatic steatosis (NASH), 271
- non-esterified fatty acid (NEFA), 69–70, 78–9
- nonsteroidal anti-inflammatory drugs (NSAIDs), allergic
 - reactions to, 124, 124*t*
- noradrenaline, 279
- norepinephrine
 - in appetite regulation, 75, 77
 - heart failure syndrome, 184
- NOS (nitric oxide synthase), 202
- NPY (neuropeptide Y), 75, 76–7
- NSAIDs (nonsteroidal anti-inflammatory drugs), allergic
 - reactions to, 124, 124*t*
- NSP/NSC (symptom profile/change scores), 213
- NSS (neuropathy symptom score), 213
- NT-3 (neurotrophin-3), 217
- nuclear receptors, 10, 19
- nucleic acids
 - identification, 26
 - labeling, 26
 - sequencing, 26–7
- nucleosomes, 2–3
- nutrient deficiency diseases, 268
 - case scenario, 274
 - complications, 269
 - diagnosis, 268, 272*t*
 - management, 271
 - nutrient balance in, 268
- nutrition
 - amino acid requirements in, 266
 - health and, 265
 - macronutrient/energy requirements, 264, 267*t*
 - nutrient resynthesis, 268
 - nutrient storage capacities, 270*t*
 - nutrient storage *versus* supply, 267
 - three pillars of, 264*t*
 - vitamin deficiency in, 267
- obesity, 69
 - adiponectin, 79
 - alcoholic liver disease and, 247, 253
 - appetite inhibition. *See* appetite inhibition
 - appetite regulation. *See* appetite regulation
 - behavioural therapy, 80
 - cardiovascular disease and, 77, 78, 79–80, 172, 189, 271
 - case studies, 82–3
 - consequences, 77–9
 - definition/classification, 69–70, 70*t*
 - diagnosis, 69, 70
 - dietary therapy, 80
 - dyslipidaemia, 78
 - economic consequences, 78
 - energy expenditure in. *See* energy expenditure
 - environmental factors, 72–3
 - epidemiology, 69
 - etiology, 70, 71*t*, 73, 272
 - exercise therapy, 79–80
 - fat topography, 69–70
 - insulin resistance, 77, 78–9
 - macronutrient balance in, 264
 - medical consequences, 273*t*
 - mutations, 71, 75–7
 - patient assessment, 79–80
 - pharmacologic treatment, 80–1
 - psychological consequences, 78, 301
 - renal cell carcinoma and, 227
 - resistin, 79
 - sleep apnoea/Pickwian Syndrome, 78
 - smoking and, 293
 - surgery, 81–2
 - thermic effect of food, 77
 - thrifty genotype/phenotype hypothesis, 71–2
 - treatment, 79
- obsessional compulsive disorder, 292*t*
- oculomotor apraxia, 50*t*
- oophoritis, thymectomy induction of, 102
- ophthalmopathy, thyroid-associated, 110, 111–12
- opioids, allergic reactions to, 124*t*
- orexin A/B, 75
- orlistat, 80
- osteoarthritis, 79–80
- oxidative stress
 - cerebral ischemia, 202, 204
 - diabetic neuropathy, 216
- p21 function, 10–11
- p53, 19–20, 35–6
- PACI (partial anterior circulation infarction), 195
- PAF (platelet-activating factor), 137, 203
- painful neuropathy, 212
- panic disorder, 292*t*

- Papillon-Lefèvre syndrome (keratopalmar periodontitis), 43*t*
- paracetamol, 250
- paraneoplastic syndromes, 227
- parasitic infections. *See also specific infection*
- allergic response, 122
 - immune response, 142*t*
 - T_H1/T_H2 cells in response to, 144
- paraventricular nucleus, 75
- Parkinson's disease, 55
- partial anterior circulation infarction (PACI), 195
- PCR, 27–8, 34–5
- PDGF (platelet derived growth factor), unstable
- angina, 170
- PDMP homologues, in Gaucher's disease, 62–3, 64
- penicillamine A, 98–101
- penicillin allergy, 125
- pentoxyfilline, 163
- peripheral tolerance, 92–3
- pernicious anemia, 102
- PfEMP-1 (*Plasmodium falciparum* erythrocyte membrane protein 1), 162
- PFGE (pulsed field electrophoresis), 25–6
- phagolysosomes, formation of, 42
- phenytoin, 219
- Philadelphia chromosome, 18, 35–6
- phosphatidylinositol 4, 5-bisphosphate (PIP₂), 13, 14*f*
- phosphoinositide (PI) signaling, 12, 14*f*
- phospholamban, 186
- phospholipid/calcium signaling, 12, 14*f*
- phosphorylation, in protein synthesis, 8–9
- PICH (primary intracerebral hemorrhage), 191, 197
- Pickwickian Syndrome, 78
- PIP₂ (phosphatidylinositol 4, 5-bisphosphate), 13, 14*f*
- Pit-1/GHF-1, 5, 71
- PKC. *See* protein kinase C (PKC)
- plasma exchange, 98–101
- Plasmodium falciparum* erythrocyte membrane protein 1 (PfEMP-1), 162
- Plasmodium falciparum* infection. *See* malaria
- platelet activating factor (PAF), 137, 203
- platelet derived growth factor (PDGF), 170
- PMS (pure motor stroke), 196
- POCI (posterior circulation infarction), 195, 195*f*
- point mutations
- in Gaucher's disease, 50, 52
 - methods of analysis, 33–4
- polymerases, 22
- polyol pathway, in diabetic neuropathy, 216
- POMC gene mutation, 71, 75–7
- Pompe's disease, 43*t*
- enzyme replacement therapy, 62*t*
 - epidemiology, 48*t*
 - treatment, 60, 62*t*
- posterior cerebral arteries, 193
- posterior circulation infarction (POCI), 195, 195*f*
- posterior communicating artery, 193
- postpartum thyroiditis, 108, 112
- post traumatic stress disorder (PTSD), 292*t*
- PPAR γ mutation, in obesity, 71
- Prader-Willi syndrome, 71
- precocious puberty, membrane receptor alterations in, 18
- prednisolone, 148, 258
- pregabalin, 219
- pregnancy
- autoimmune hypothyroidism, 106
 - Grave's disease, 108, 112
 - malarial hypoglycemia, 165
- primary culture analysis, 36
- primary intracerebral hemorrhage (PICH), 191, 197
- proinflammatory cytokines
- in acquired immunity, 145
 - in innate immunity, 137, 140, 142
 - metabolism suppression by, 264
 - principal/actions overview, 144*t*
 - tuberculosis, 147, 148, 156
- promoter elements
- in gene transcription, 3
 - methods of analysis, 29
- pronuclear injection approach, 31
- propylthiouracil, 258
- prostaglandins, 116–19, 137
- protein kinase A, 12, 16
- protein kinase C (PKC)
- in diabetic neuropathy, 217
 - mutations, 18
 - in signal transduction, 13, 16–17
- protein metabolism, in alcoholic liver disease, 249
- protein requirements, 267*t*
- protein synthesis
- mRNA in, 5–9
 - post-translational processing, 8–9
 - secretion, 8
- protein transcription, gene structure and, 2
- proviral transcription, HIV-1, 150, 151*f*
- provirus formation, HIV-1, 150
- proximal motor neuropathy, 211
- pseudo-Hurler polydystrophy, 43*t*

Cambridge University Press

978-0-521-52318-9 - Mechanisms of Disease: An Introduction to Clinical Science, Second Edition

Stephen Tomlinson, Anthony M. Heagerty, Anthony P. Weetman and Rayaz A. Malik

Index

[More information](#)

- psychiatric illness, 286, 297. *See also specific disease*
 clinical scenarios, 302
 diagnosis, 288
 due to brain disorder, 291
 due to organic disease, 290, 291, 292
 emotional response to disease and, 286
 factors affecting, 288, 297
 independent concurrence, 297
PTPN22, 104–6, 108
 PTSD (post traumatic stress disorder), 292*t*
 pulmonary edema, 165, 165*f*
 pulmonary tuberculosis, 147*f*
 pulsed field electrophoresis (PFGE), 25–6
 pure motor stroke (PMS), 196
 pyknodysostosis, 43*t*
- quantitative sensory tests (QSTs), 213
 quinine, 165
- rantes, 144*t*
 RCC. *See* renal cell carcinoma (RCC)
 reactive nitrogen intermediates (RNIs), 147, 147*f*
 reactive oxygen intermediates (ROIs), 147, 147*f*
 receptor-mediated endocytosis, 42, 45–6, 47
 receptor-operated calcium channels (ROCs), 13–15
 recombination, 2
 re-feeding Syndrome, 269
 relapsing fever, 140, 142*t*
 renal cell carcinoma (RCC)
 chimeric immune receptor, 235
 clinical scenario, 239
 diagnosis, 227
 epidemiology, 227
 etiology, 227
 histopathology, 228
 immune therapies, 229, 234, 236
 multi-kinase inhibitors, 238
 pharmacologic treatment, 229
 radiation, 229
 stem cell transplantation, 236
 surgery, 228, 236
 treatment, 228
 tumor infiltrating lymphocytes, 235
 vaccine therapy, 235
 renal oncocytoma, 228
 renin-angiotensin system, 184
 reperfusion therapy, 198, 205
 repetitive sequences, 2–3
 repression of transcription factors, 5, 16
 repressor elements, in gene transcription, 3
 resistin, 79
 resting metabolic rate (RMR), 77
 restriction fragment length polymorphisms (RFLPs), 33
 restrictive surgery, bariatric, 81
 reticuloendothelial system, in alcoholic liver disease, 255
 retinitis pigmentosa, 18
 retinoblastoma gene (Rb)
 in cell cycle regulation, 20–1
 in gene therapy, 35–6
 retinoic acid, in signal transduction, 10
 reverse transcriptase, 22
 reverse transcription, in HIV-1 infection, 150, 151*f*
 RFLPs (restriction fragment length polymorphisms), 33
 RGB (Roux-en-Y gastric bypass), 81–2
 rheumatoid arthritis, 95, 98–101
 riboflavin assessment, 272*t*
 ribosomal RNA (rRNA), 6–7
 ribosomes, in mRNA translation, 6–7
 ribozymes, 36
 Richet, Charles, 124
 rimonabant, 81
 RMR (resting metabolic rate), 77
 RNA
 heterogeneous nuclear, 5–6
 messenger. *See* messenger RNA (mRNA)
 ribosomal, 6–7
 t-, 7
 RNIs (reactive nitrogen intermediates), 147, 147*f*
 road crash scenario
 arterial baroreceptor reflex, 277
 blood loss, cardiovascular response, 277
 chemoreceptor reflex, 278
 depressor reflex, 277
 event, 276
 injuries, effects of, 276
 management, 282
 tissue damage, 278
 ROCs (receptor-operated calcium channels), 13–15
 ROIs (reactive oxygen intermediates), 147, 147*f*
 rosettes, malarial, 162
 rosiglitazone, resistin inhibition by, 79
 Rous sarcoma virus, 18
 Roux-en-Y gastric bypass (RGB), 81–2
 ryanodine receptor, 13–15, 186
- SAH (subarachnoid hemorrhage), 191, 197
 Salla disease, 42, 43*t*, 45
 Sandhoff disease, 43*t*, 46–7, 48*t*

Cambridge University Press

978-0-521-52318-9 - Mechanisms of Disease: An Introduction to Clinical Science, Second Edition

Stephen Tomlinson, Anthony M. Heagerty, Anthony P. Weetman and Rayaz A. Malik

Index

[More information](#)

322 Index

- Sanfilippo diseases, 43*t*
 saposins A-D, 42, 43*t*, 45
 sap precursor, 43*t*
 Schindler disease, 43*t*
Schistosoma mansoni, 142*t*
 schizophrenia, 293, 295, 301
 sclerosing hyaline necrosis. *See* alcoholic hepatitis
 scombrototoxin poisoning, 124*t*
 second messenger-operated calcium channels (SMOCs), 13–15
 E-selectin
 alcoholic liver disease, 251
 cerebral ischemia, 203
 cytoadherence mediation by, 162
 P-selectin, 203
 Semmes-Weinstein Monofilaments, 213
 sepsis, bacterial, 140, 142*t*
 sequestration, in severe malaria, 162
 SERCA protein, in heart failure syndrome, 186
 serotonin (5HT), 76
 shock, anaphylactic, 122
 sialidosis, 43*t*
 sibutramine, 80–1
 signal transduction, 9
 alterations in, 18–19
 cAMP in, 77
 effector elements in, 9
 EGF in, 9–10
 gene transcription and, 16–17
 G protein, 10–11
 G-protein-independent receptors, 9–10
 G-protein-linked receptors, 9
 heart failure syndrome, 187
 inositol 1, 4, 5-triphosphate (IP₃), 13, 14*f*, 16
 Janus kinases, 9–10
 lysosomal enzymes, 42–5
 membrane receptors, 9–10, 18
 nuclear receptors, 10, 19
 phospholipid/calcium signaling, 12–16
 protein kinase A, 12, 16
 protein kinase C, 13, 16–17
 transducer elements in, 9
 tyrosine kinase proteins, 9–10
 sildenafil, 220
 single-strand conformational polymorphism (SSCP), 35
 sleep apnoea, 78
 SLE (systemic lupus erythematosus), 96–7
 slow-reacting substance of anaphylaxis (SRS-A), 137
 Sly disease, 43*t*
 small cell lung cancer, 20–1
 small vessel disease, 197
 smoking
 acute coronary syndromes, 171*t*
 heart failure syndrome, 189
 and psychiatric disorders, 293, 299
 renal cell carcinoma, 227
 social phobia, 292*t*
 sodium balance, in obesity, 271
 sorafenib (Nexavar), 238
 Southern blotting, 32, 33
 specific-acquired immunity, 140
 anaphylaxis. *See* anaphylaxis
 antigen presentation, 140
 CD4+/CD8+ cells, 143*t*
 co-receptor molecules in, 140
 co-stimulatory molecules in, 140
 immunopathology, 142*t*
 viral infections, 56, 142*t*
 specific phobia, 292*t*
 sphingolipid activator proteins, 42–5
 sphingolipid activator protein (saposin) deficiency, 42, 43*t*, 45
 sphingolipidoses, 43*t*
 splenectomy, for Gaucher's disease, 56
 SSCP (single-strand conformational polymorphism), 35
 start codons, degeneracy in, 42–5
 Stauffer syndrome, 227
 stem cell transplantation, for renal cell carcinoma, 236
 steroid hormones, in signal transduction, 10
 steroids. *See also* corticosteroids; glucocorticoid(s), 119, 148
 stop codons, degeneracy in, 42–5
Streptococcus pneumoniae, 140, 142*t*
 streptokinase, 171
 stress
 in autoimmunity, 97–8
 Grave's disease, 108
 oxidative. *See* oxidative stress
 stroke, 191, 205
 abbreviations, 209
 anterior circulation syndromes, 195, 195*f*
 aspirin, 191, 205
 atherothromboembolism, 197
 brain imaging, 204
 cardioembolism, 197
 cerebral ischemia. *See* cerebral ischemia
 classification, 193
 clinical presentation, 193

Cambridge University Press

978-0-521-52318-9 - Mechanisms of Disease: An Introduction to Clinical Science, Second Edition

Stephen Tomlinson, Anthony M. Heagerty, Anthony P. Weetman and Rayaz A. Malik

Index

[More information](#)

- clinical scenarios, 207
- gene expression, 201, 201*f*
- hemodynamic infarction, 197
- lacunar infarctions, 196, 196*f*
- MCA territory ischemia, 197, 198*f*
- neuroprotection, 191, 198, 205
- NF- κ B pathway, 201
- pharmacological treatment, 205
- posterior circulation syndromes, 195, 195*f*
- reperfusion therapy, 198, 205
- risk factors, 197
- small vessel disease, 197
- stroke units, 204
- t-PA (tissue plasminogen activator), 205
- subarachnoid hemorrhage (SAH), 191, 197
- substance P, 73
- substrate reduction treatment, for Gaucher's disease, 62–3
- subtractive hybridisation, 24–5
- sunitinib, 238
- sweating abnormalities, in diabetes, 213, 220
- symptom profile/change scores (NSP/NSC), 213
- syphilis, 140
- systemic lupus erythematosus (SLE), 96–7

- TACI (total anterior circulation infarction), 195, 195*f*
- tacrolimus, 98–101
- tadalafil, 220
- tamoxifen, 229
- targeted dominant negative receptor mutants, 32
- TATA motif, transcription of, 70
- Tay-Sachs disease, 43*t*, 48*t*
- T-cell (cell-dependent) immunity
 - alcoholic liver disease, 255
 - anergy in, 88, 92–3. *See also* anergy
 - antigen-specific, generation of, 235
 - clonal deletion, 90–1
 - in EAT etiology, 102–4
 - as factor in autoimmune disease, 85–6
 - stimulation in immune response, 87–9, 143*t*
 - suppression, 93, 94–5
 - T_H1 cells in, 144
 - thyroid autoantigen, response to, 106–8
 - TSH receptor antibodies, 108–10
- T cell receptor (TCR)
 - in anergy, 92–3. *See also* anergy
 - in immune response, 85–6, 87–9, 90–1, 230, 231, 233
 - structure, 87–9, 233
 - thyroid autoantigen, response to, 106–8
 - vaccination in disease prevention, 93
- TCR-CD3 complex, in specific-acquired immunity, 140
- TCR-CD3 complex binding
 - antigen-presenting cells in, 140
 - B7 in, 140, 143*t*
 - CTLA-4 in, 140, 143*t*
 - ICAM-1 in, 140, 143*t*
 - MHC in, 140, 230
- testicular feminisation syndrome, 19
- testosterone, in autoimmunity, 97–8, 106
- TGF- β . *See* transforming growth factor (TGF)- β
- T_H1 cells, 144, 144*t*
- T_H2 cells, 144, 144*t*
- b-thalassaemias, point mutations in, 33–4
- thalidomide
 - for erythema nodosum leprosum, 157
 - for tuberculosis, 148
- thermal threshold testing, 213
- thermic effect of food, 77
- thermogenesis, cellular mechanisms of, 77
- thiamine assessment, 272*t*
- thiazolidinediones (TZDs)
 - adiponectin stimulation by, 79
 - resistin inhibition by, 79
- three-dimensional folding in protein synthesis, 8–9
- thrifty genotype/phenotype hypothesis, 71–2
- thrombolytic drugs, 205
- thrombospondin, cytoadherence mediation by, 162
- thromboxanes, 137
- thymectomy, 102
- thyroglobulin, 101, 102–4, 106–8
- thyroid-associated ophthalmopathy, 110, 111–12
- thyroid disorders. *See* Graves' disease (hyperthyroidism); Hashimoto's thyroiditis (hypothyroidism)
- thyroid gland, self-antigen expression in, 90–1
- thyroid hormones, in signal transduction, 10
- thyroid neoplasms, membrane receptor alterations, 18
- thyroid peroxidase, 106–8
- thyroid-stimulating hormone (TSH) receptor
 - autoimmune hypothyroidism, 106–8
 - Grave's disease, 108–10
 - membrane receptor alterations, 18, 19
- thyrotoxicosis, 178
- TIA (transient ischaemic attack), 191
- TILs (tumor infiltrating lymphocytes), 235
- tissue inhibitors of MMPs (TIMPs), 216

Cambridge University Press

978-0-521-52318-9 - Mechanisms of Disease: An Introduction to Clinical Science, Second Edition

Stephen Tomlinson, Anthony M. Heagerty, Anthony P. Weetman and Rayaz A. Malik

Index

[More information](#)

- tissue plasminogen activator (t-PA), 205
 TLRs (toll-like receptors), 147
 TNF- α . *See* tumor necrosis factor- α
 toll-like receptors (TLRs), 147
 topiramate, 219
 toremifene, 229
 total anterior circulation infarction (TACI), 195, 195*f*
 TPA-response element (TRE), 17
 t-PA (tissue plasminogen activator), 205
 tramadol, 219
 trandolopril, 217
 transducer elements, in signal transduction, 9
trans-elements, in gene transcription, 3
 transforming growth factor (TGF)- β , 144*t*
 glycation in diabetic neuropathy, 216
 unstable angina, 170
 transgenic animals, 29–32
 transient ischaemic attack (TIA), 191
 transient thyrotoxicosis, 108–10
 transplantation
 rejection treatment, 98–101
 stem cell, 236
 transportation defect diseases, 43*t*
 trauma, 275
 adrenaline response to, 279
 alcohol in, 278
 anxiety following, 291
 arterial baroreceptor reflex, 277
 blood loss, cardiovascular response, 277
 blood testing, 281
 chemoreceptor reflex, 278
 clinical scenarios, 285. *See also* road crash scenario
 complement system, 279
 cortisol in, 279
 cytokines, 279
 depressor reflex, 277
 epidemiology, 275
 Glasgow Coma Scale, 281
 insulin/glucagon, 279
 management, 280
 MOFS/ARDS, 282
 patient monitoring, 281
 physiology, normalization of, 280
 prevention, 276
 tissue damage, 278
 T regulatory cells, 93
Treponema pallidum, 140
 TRE (TPA-response element), 17
 tricyclic drugs, 219
 trisomy 7/17, 228
 tRNA, 7
 troponin C, 174
 truncal neuropathies, 211
 TSH receptor. *See* thyroid-stimulating hormone (TSH)
 receptor
 tubercular meningitis, 156
 tuberculoid leprosy, 145
 tuberculosis, 145
 anaphylactic reactions in, 145
 CD14 in, 148
 chemokines, 147
 glucocorticoids for, 148
 host response, 147
 immunomodulating drugs and, 148
 immunopathology, 147*f*
 interferon γ , 147
 interleukins in, 147
 proinflammatory cytokines in, 147, 148, 156
 pulmonary, 147*f*
 RNIs/ROIs in, 147, 147*f*
 TLRs in host response, 147
 tumor necrosis factor- α , 148, 156
 tuberculosis/HIV-1 coinfection, 147, 155, 155*f*
 clinical effects, 155
 epidemiological effects, 155
 histological effects, 154
 tumor infiltrating lymphocytes (TILs), 235
 tumor necrosis factor- α , 144*t*
 alcoholic liver disease, 251, 255
 in autoimmune hypothyroidism, 104–6
 biological effects of, 148*t*
 cerebral ischemia, 200, 201, 202
 chronic inflammation, 144
 in erythema nodosum leprosum, 157
 heart failure syndrome, 184
 in immune response, 96–7
 in inflammation, 142
 in innate immunity, 137, 140
 in malaria, 162, 163
 mutations, malaria, 166
 in obesity, 79
 proviral transcription, HIV-1, 150
 thyroid autoantigen, response to, 106–8
 tuberculosis, 148, 156
 tumor necrosis factor- β , 144*t*
 tumor suppressors, in cell cycle regulation, 19–21
 tyrosine kinase proteins, 9–10, 18
 TZDs. *See* thiazolidinediones (TZDs)

Cambridge University Press

978-0-521-52318-9 - Mechanisms of Disease: An Introduction to Clinical Science, Second Edition

Stephen Tomlinson, Anthony M. Heagerty, Anthony P. Weetman and Rayaz A. Malik

Index

[More information](#)

- uncoupling proteins (UCPs), 77
- unstable angina, 170, 171, 173, 174
- vaccine therapy, 235
- vagus nerve, 73
- vancomycin, 124*t*
- vardenafil, 220
- vascular endothelial growth factor (VEGF), 218
- vascular tone changes, in cerebral ischemia, 203
- VBG (vertical banded gastroplasty), 81
- VCAM-1, 162, 251
- vector cloning, 23
- VEGF (vascular endothelial growth factor), 218
- ventral medial hypothalamus, 75
- vertebral arteries, 193
- vertical banded gastroplasty (VBG), 81
- very low calorie diet (VLCD), 80
- vibration perception testing, 213
- vinblastine, 229
- viral hepatitis, 253
- viral infections. *See also specific infection*
 - in Gaucher's disease, 56. *See also* Gaucher's disease
 - immune response to, 142*t*
 - specific-acquired immunity, 145
- vitamin A, 272*t*
- vitamin B12, 268, 272*t*
- vitamin C, 271, 272, 272*t*
- vitamin D
 - assessment, 272*t*
 - deficiency, 19, 274
 - in signal transduction, 10
- vitamin deficiency diseases
 - assessment, 272*t*
 - case scenario, 274
 - mechanisms, 267, 271, 272
- vitamin E, 271, 272, 272*t*
- vitamin K, 272*t*
- VLCD (very low calorie diet), 80
- voltage-operated calcium channels (VOCs), 13–15
- Von Hippel Lindau syndrome, 227
- waist circumference (WCR), 70
- waist-hip ratio (WHR), 70
- wasp stings
 - allergic reactions to, 121
 - avoidance, 127
 - clinical scenario, 129, 132
- Wolman's disease, 43*t*, 46–7, 48*t*
- X-linked Hunter's disease, 45–6
- Zavesca (miglustat), 54*f*, 64
- zinc deficiency, 267, 268
- zinc fingers, in gene transcription, 3–4